1) Willing and able to give signed informed consent for participation in the study <br/ > 2)Male or female subject greater than or equal to 18 years of age at screening <br/ > 3) Women of child-bearing potential <br/ > -Have to agree to use an acceptable birth control method during participation in the investigation <br/ > -A negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at Day 1 will be required. Country specific India: Serum pregnancy test will be used instead of urine <br/ > 4) Asymptomatic or mildly infected COVID-19 patients as per Indian guidelines for Indian sites. NIH criteria will be used for Sweden <br/ > 5) Duration of symptoms not exceeding 6 days prior to baseline/IMP administration (Day 1) <br/ > 6) A positive RT-PCR test no older than 72 hours for SARS-CoV-2. The positive result must be available no later than 6 days from initiation of symptoms, if any

1) Willing and able to give signed informed consent for participation in the study <br/ > 2)Male or female subject greater than or equal to 18 years of age at screening <br/ > 3) Women of child-bearing potential <br/ > -Have to agree to use an acceptable birth control method during participation in the investigation <br/ > -A negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at Day 1 will be required. Country specific India: Serum pregnancy test will be used instead of urine <br/ > 4) Asymptomatic or mildly infected COVID-19 patients as per Indian guidelines for Indian sites. NIH criteria will be used for Sweden <br/ > 5) Duration of symptoms not exceeding 6 days prior to baseline/IMP administration (Day 1) <br/ > 6) A positive RT-PCR test no older than 72 hours for SARS-CoV-2. The positive result must be available no later than 6 days from initiation of symptoms, if any